uric acid has been researched along with Tumour Lysis Syndrome in 112 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Control of serum uric acid (sUA) levels is very important during chemotherapy in patients with malignant tumors, as the risks of tumor lysis syndrome (TLS) and renal events are increased with increasing levels of sUA." | 9.22 | Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. ( Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T, 2016) |
| "Patients with hematologic malignancies at intermediate to high TLS risk grade were randomized to receive febuxostat or allopurinol, starting 2 days before induction chemotherapy, for 7-9 days." | 9.20 | FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. ( Aurer, I; Baldini, S; Borsaru, G; Bosi, A; Capriati, A; Federico, M; Glushko, NL; Grosicki, S; Jakucs, J; Jordan, K; Maggi, CA; Mayer, J; Montesinos, P; Nagy, Z; Pristupa, AS; Rego, EM; Ribera, JM; Ristic, D; Scartoni, S; Simonelli, C; Spina, M, 2015) |
| "In adults with hyperuricemia or at high risk for TLS, rasburicase provided control of plasma uric acid more rapidly than allopurinol." | 9.14 | Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. ( Abboud, CN; Brown, A; Cortes, J; Craig, M; Dey, BR; Krishnamurthy, M; Laadem, A; Luger, S; Matous, J; Maziarz, RT; Moore, JO; Pham, D; Schiller, GJ; Seiter, K; Wetzler, M, 2010) |
| "Tumour lysis syndrome is an oncological emergency, characterized by rapid cytolysis leading to an abrupt rise of serum uric acid levels." | 9.01 | Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis. ( Bellos, I; Kontzoglou, K; Pergialiotis, V; Psyrri, A, 2019) |
| "Uric acid drives acute kidney injury in tumor lysis syndrome (TLS)." | 8.02 | Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome. ( Barreto, EF; Habermann, TM; Leung, N; Mara, KC; May, HP, 2021) |
| "While rasburicase has shown efficacy to rapidly correct hyperuricemia compared with allopurinol, its overall impact in improving clinically significant outcomes, such as acute kidney injury (AKI), in tumor lysis syndrome (TLS) is unknown." | 7.96 | Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. ( Estey, E; Frieze, D; Garcia, DA; Hingorani, S; Khalighi, PR; Li, A; Li, S; Martens, KL; Silgard, E; White, AA, 2020) |
| "The aim of the present study was to determine if febuxostat could prevent tumor lysis syndrome (TLS) in children who received induction chemotherapy for hematologic malignancies." | 7.85 | Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. ( Hori, D; Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D, 2017) |
| "The aim of the study was to compare reductions in uric acid (UA), length of stay (LOS), and hospitalization costs in patients with tumor lysis syndrome (TLS) treated with rasburicase or allopurinol." | 7.85 | A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome. ( Cairo, MS; Eaddy, MT; Tangirala, K; Thompson, S, 2017) |
| "We investigated the ability of serum uric acid (SUA) to predict laboratory tumor lysis syndrome (LTLS) and compared it to common laboratory variables, cytogenetic profiles, tumor markers and prediction models in acute myeloid leukemia patients." | 7.81 | Uric acid and the prediction models of tumor lysis syndrome in AML. ( Ejaz, AA; Hsu, JW; Johnson, RJ; Mohandas, R; Pourafshar, N; Smallwood, BA, 2015) |
| "Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, and control of serum uric acid level (S-UA) is most important." | 7.80 | Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study. ( Iwasaki, H; Kishi, S; Matsuda, Y; Nakamura, T; Ookura, M; Tai, K; Takai, M; Ueda, T; Yamauchi, T; Yoshida, A, 2014) |
| "Control of serum uric acid (sUA) levels is very important during chemotherapy in patients with malignant tumors, as the risks of tumor lysis syndrome (TLS) and renal events are increased with increasing levels of sUA." | 5.22 | Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. ( Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T, 2016) |
| "Patients with hematologic malignancies at intermediate to high TLS risk grade were randomized to receive febuxostat or allopurinol, starting 2 days before induction chemotherapy, for 7-9 days." | 5.20 | FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. ( Aurer, I; Baldini, S; Borsaru, G; Bosi, A; Capriati, A; Federico, M; Glushko, NL; Grosicki, S; Jakucs, J; Jordan, K; Maggi, CA; Mayer, J; Montesinos, P; Nagy, Z; Pristupa, AS; Rego, EM; Ribera, JM; Ristic, D; Scartoni, S; Simonelli, C; Spina, M, 2015) |
| "In adults with hyperuricemia or at high risk for TLS, rasburicase provided control of plasma uric acid more rapidly than allopurinol." | 5.14 | Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. ( Abboud, CN; Brown, A; Cortes, J; Craig, M; Dey, BR; Krishnamurthy, M; Laadem, A; Luger, S; Matous, J; Maziarz, RT; Moore, JO; Pham, D; Schiller, GJ; Seiter, K; Wetzler, M, 2010) |
| "Tumour lysis syndrome is an oncological emergency, characterized by rapid cytolysis leading to an abrupt rise of serum uric acid levels." | 5.01 | Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis. ( Bellos, I; Kontzoglou, K; Pergialiotis, V; Psyrri, A, 2019) |
| "Although urate oxidase might be effective in reducing serum uric acid, it is unclear whether it reduces clinical tumour lysis syndrome, renal failure, or mortality." | 4.90 | Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. ( Chan, GC; Cheuk, DK; Chiang, AK; Ha, SY, 2014) |
| " The treatment consists in hydration, correction of the acidosis and hyperkalemia, use of allopurinol and recombinant urate oxidase (rasburicase) for preventing urate nephropathy and haemodialysis." | 4.84 | [The pathophysiology, clinical signs and therapy of urate nephropathy]. ( Méhes, L; Rejto, L; Szász, R; Udvardy, M, 2007) |
| " A rapid and massive raise of uric acid, during tumor lysis syndrome (TLS), and also a lower and chronic hyperuricemia, as in gout, mainly damage the kidney." | 4.84 | Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. ( Cammalleri, L; Malaguarnera, M, 2007) |
| " However, ARF may also develop due to aetiologies arising from cancer treatment or the disease itself, including: nephrotoxic chemotherapy agents, post-renal obstruction, compression and infiltration by malignancy, tumour lysis syndrome, uric acid, sepsis and contrast agent nephropathy." | 4.82 | Acute renal failure in cancer patients. ( Flombaum, CD; Lameire, NH; Moreau, D; Ronco, C, 2005) |
| "A patient with bulky metastatic melanoma was treated with concurrent biochemotherapy using interleukin-2, interferon-alpha, and a combination of cisplatin, vinblastine, and dacarbazine." | 4.80 | Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. ( Castro, MP; Legha, S; Spencer-Cisek, P; Sponzo, RW; VanAuken, J, 1999) |
| "Uric acid drives acute kidney injury in tumor lysis syndrome (TLS)." | 4.02 | Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome. ( Barreto, EF; Habermann, TM; Leung, N; Mara, KC; May, HP, 2021) |
| "While rasburicase has shown efficacy to rapidly correct hyperuricemia compared with allopurinol, its overall impact in improving clinically significant outcomes, such as acute kidney injury (AKI), in tumor lysis syndrome (TLS) is unknown." | 3.96 | Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. ( Estey, E; Frieze, D; Garcia, DA; Hingorani, S; Khalighi, PR; Li, A; Li, S; Martens, KL; Silgard, E; White, AA, 2020) |
| " Adherence to guidelines has not been well studied, and the correlation between uric acid reduction and clinically relevant outcomes, such as acute kidney injury, remains unclear." | 3.96 | Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. ( Frieze, D; Garcia, DA; Khalighi, PR; Li, A; Li, S; Martens, KL; Silgard, E; White, AA, 2020) |
| "Early administration of rasburicase to enhance uric acid (UA) elimination has been adopted without robust evidence in support of its impact on clinical outcomes in tumor lysis syndrome (TLS), specifically, the prevention of acute kidney injury (AKI)." | 3.91 | Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. ( Barreto, EF; Dierkhising, R; Habermann, TM; Leung, N; McCullough, KB; Personett, HA, 2019) |
| "The aim of the present study was to determine if febuxostat could prevent tumor lysis syndrome (TLS) in children who received induction chemotherapy for hematologic malignancies." | 3.85 | Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. ( Hori, D; Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D, 2017) |
| "The aim of the study was to compare reductions in uric acid (UA), length of stay (LOS), and hospitalization costs in patients with tumor lysis syndrome (TLS) treated with rasburicase or allopurinol." | 3.85 | A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome. ( Cairo, MS; Eaddy, MT; Tangirala, K; Thompson, S, 2017) |
| "Fixed, low dose rasburicase produced a consistent lowering of uric acid levels and may be utilized in the management of hyperuricemia in TLS." | 3.81 | Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients. ( Dinh, BC; Herrington, JD, 2015) |
| "Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function." | 3.81 | Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia. ( Prasada, H, 2015) |
| "We investigated the ability of serum uric acid (SUA) to predict laboratory tumor lysis syndrome (LTLS) and compared it to common laboratory variables, cytogenetic profiles, tumor markers and prediction models in acute myeloid leukemia patients." | 3.81 | Uric acid and the prediction models of tumor lysis syndrome in AML. ( Ejaz, AA; Hsu, JW; Johnson, RJ; Mohandas, R; Pourafshar, N; Smallwood, BA, 2015) |
| "Tumor lysis syndrome (TLS) is a life-threatening oncological emergency, and control of serum uric acid level (S-UA) is most important." | 3.80 | Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study. ( Iwasaki, H; Kishi, S; Matsuda, Y; Nakamura, T; Ookura, M; Tai, K; Takai, M; Ueda, T; Yamauchi, T; Yoshida, A, 2014) |
| " Careful evaluation of serum electrolytes, uric acid, and renal function must occur." | 3.80 | Tumor lysis syndrome: risk factors, diagnosis, and management. ( Burns, RA; Reynolds, SL; Topoz, I, 2014) |
| "In order to elucidate the mechanism of hyperuricemia in hematologic malignancies, we have retrospectively investigated the uric acid metabolism in 418 chemotherapy-naïve patients with hematologic malignancies." | 3.80 | Hyperuricemia in hematologic malignancies is caused by an insufficient urinary excretion. ( Akiyama, N; Fujimori, S; Kawasugi, K; Oka, Y; Shirafuji, N; Sirasaki, R; Tashiro, H; Yamamoto, T, 2014) |
| "Rasburicase is indicated for the initial management of plasma uric acid levels in adults receiving anticancer therapy who are at risk for acute tumor lysis syndrome (TLS) and subsequent hyperuricemia." | 3.76 | Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. ( Shanholtz, CB; Thompson, JL; Vines, AN, 2010) |
| "We report the case of a patient with chronic lymphatic leukemia (CLL) who experienced tumor lysis syndrome (TLS) with acute renal failure after fludarabine/cyclophosphamide chemotherapy and after bendamustine treatment." | 3.73 | Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. ( Adam, K; Bergmann, J; Buchheidt, D; Hehlmann, R; Hummel, M; Reiter, S, 2005) |
| "2 mg/kg once/day for 5 days in pediatric patients with cancer to lower plasma uric acid concentrations and manage tumor lysis syndrome (TLS)." | 3.73 | Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. ( Frei-Lahr, DA; Hall, PD; Hayslip, J; Lenz, KL; McDonnell, AM, 2006) |
| " In addition, she received allopurinol 300 mg daily for prevention of tumor lysis syndrome (TLS)." | 3.72 | Use of single-dose rasburicase in an obese female. ( Arnold, TM; Delman, BS; Reuter, JP; Shanholtz, CB, 2004) |
| "We report a 67-year-old man with acute uric acid nephropathy, secondary to spontaneous tumor lysis syndrome, that presented itself as a huge intra-abdominal tumor that led to acute renal failure, hyperuricemia, and azotemia." | 3.71 | An enormous abdominal mass associated with acute renal failure. ( Chen, YC; Fang, JT; Hsu, HH; Huang, CC; Lin, CL, 2001) |
| " The vast majority of these patients had a malignancy and were in danger of developing tumor lysis syndrome (TLS) and subsequent acute uric acid nephropathy (AUAN) and were unable to take oral allopurinol." | 3.70 | Allopurinol: intravenous use for prevention and treatment of hyperuricemia. ( Anderson, SA; Cederberg, D; Guaspari, A; Haase-Statz, S; Hohneker, JA; Smalley, RV, 2000) |
| "A 52-year-old man with retroperitoneal nodal, lung, and liver metastases from choriocarcinoma received chemotherapy with etoposide, cisplatin, and bleomycin." | 3.70 | Acute tumor lysis syndrome with choriocarcinoma. ( Blanke, CD; Hemmer, MP; Witte, RS, 2000) |
| "15 mg/kg) administered as single dose followed by as needed dosing (maximum five doses) versus daily dosing for 5 days in adult patients at risk for TLS." | 2.77 | A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. ( Bueso-Ramos, CE; Cortes, JE; Fanale, MA; Fayad, LE; Fowler, N; Hagemeister, FB; Kwak, LW; McLaughlin, PW; Orlowski, RZ; Pro, B; Rodriguez, A; Romaguera, JE; Samaniego, F; Sarlis, NJ; Shah, J; Vadhan-Raj, S; Wang, M; Younes, A; Zhou, X, 2012) |
| "Usual prophylaxis and treatment of hyperuricemia consist of hydration, alkalinization, and administration of allopurinol." | 2.71 | Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on R ( Belhadj, K; Bologna, S; Casasnovas, O; Christian, B; Coiffier, B; Fermé, C; Herbrecht, R; Jourdan, E; Mounier, N; Sonet, A; Tilly, H, 2003) |
| " This meta-analysis study evaluated the efficacy and cost savings of a single-dose rasburicase (SDR) regimen compared with the Food and Drug Administration-approved daily dosing of rasburicase (DDR) for 5 days or the traditional treatment with allopurinol in adult cancer patients with hyperuricaemia or at high risk for TLS." | 2.49 | Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. ( Bhutada, NS; Dong, K; Feng, X; Inciardi, J; Pence, S; Pham, D, 2013) |
| "Tumor lysis syndrome is a complication of malignancies caused by massive tumor cell lysis due to either spontaneous tumor cell lysis or to different therapies and it may cause hyperuricemia." | 2.44 | [Rasburicase therapy may cause hydrogen peroxide shock]. ( Góth, L, 2008) |
| "An 8-year-old boy with stage 3 Burkitt's lymphoma, TLS was successfully treated with hyper-hydration, diuretics and rasburicase, without dialysis." | 2.44 | Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature. ( Loh, TF; Tan, AM; Teo, WY, 2007) |
| "The standard prophylaxis or treatment of hyperuricemia consists of decreasing uric acid production with allopurinol and facilitating its excretion by urinary alkalinization and hyperhydration." | 2.42 | Management of hyperuricemia with rasburicase review. ( de Bont, JM; Pieters, R, 2004) |
| "Tumor lysis syndrome is a critical illness characterized by massive tumor cell death leading to severe hyperuricemia, hyperphosphatemia, hypocalcemia, and acute renal failure after starting chemotherapy to cancers, especially lymphoproliferative malignancies." | 2.39 | [Hyperuricemia and the kidney]. ( Hikita, M; Hosoya, T; Ichida, K, 1996) |
| "We aimed to evaluate the UA lowering effectiveness and provider adherence to the institutional protocol, as well as the cost-efficiency of this dosing strategy." | 1.72 | A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults. ( Hossain, S; Naber, M; Yacobucci, MJ, 2022) |
| "Tumor lysis syndrome is an oncological emergency but an exceedingly rare complication in non-hematological malignancies, including prostate cancer." | 1.62 | Urate Nephropathy from Tumor Lysis Syndrome in an Undiagnosed Case of Prostate Cancer. ( Javed, S, 2021) |
| "Indication-based, low-dose rasburicase displayed significantly more value when compared to weight-based dosing as shown by achieving cost savings without compromising clinical efficacy." | 1.51 | The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome. ( Blackman, A; Boutin, A; Forcello, N; O'Sullivan, DM, 2019) |
| "To evaluate single fixed dosing versus weight-based dosing strategies for rasburicase to determine the minimum dose required to mitigate hyperuricemia in the treatment or prevention of tumor lysis syndrome." | 1.39 | Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome. ( Augustin, KM; Boehmer, L; Butler, SK; Lathon, SC; McBride, A; Westervelt, P, 2013) |
| "96 million (96%) direct cost savings for the 48 patients in this study when compared to the cost of manufacturer's dosing recommendation." | 1.37 | Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. ( Crank, CW; Knoebel, RW; Lo, M, 2011) |
| "Spontaneous tumour lysis syndrome is rare and this case highlights the difficulties in making an early diagnosis when the presence of a predisposing tumour has not yet been identified." | 1.36 | Tumour lysis syndrome: an unusual presentation. ( Chubb, EA; Farley-Hills, E; Maloney, D, 2010) |
| " The drug dosing was calculated based on the patients' ideal body weight (IBW) or adjusted body weight (aBW) for those who were more than 30% above their IBW." | 1.35 | Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach. ( Campara, M; Haaf, CM; Shord, SS, 2009) |
| "Three children with acute lymphoblastic leukemia presenting with hyperuricemia received rasburicase as a single intravenous dose just prior to the start of chemotherapy." | 1.32 | Treatment of impending tumor lysis with single-dose rasburicase. ( Chan, R; Lee, AC; Li, CH; So, KT, 2003) |
| "Hyperuricemia is the hallmark of severe gout with tophi formation." | 1.32 | [Rasburicase (Fasturtec)]. ( Frey, FJ; Gugger, M; Vogt, B, 2004) |
| "Tumor lysis syndrome (TLS) and renal failure remain significant causes of morbidity and mortality in children with newly diagnosed Burkitt's lymphoma and high white blood cell count acute lymphocytic leukemia (ALL) despite conventional management with aggressive hydration, alkalinization, allopurinol, and the slow introduction of chemotherapy." | 1.29 | Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration. ( Berkow, RL; Kohaut, EC; Saccente, SL, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.89) | 18.7374 |
| 1990's | 17 (15.18) | 18.2507 |
| 2000's | 36 (32.14) | 29.6817 |
| 2010's | 44 (39.29) | 24.3611 |
| 2020's | 14 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| L, A | 1 |
| Reddy, JM | 1 |
| Chebbi, PG | 1 |
| Kumar, N | 1 |
| Ar, AK | 1 |
| M, P | 1 |
| B S, AK | 1 |
| Basile, DP | 1 |
| Zhang, Q | 1 |
| Zu, C | 1 |
| Meng, Y | 1 |
| Lyu, Y | 1 |
| Hu, Y | 1 |
| Huang, H | 1 |
| Ejaz, AA | 4 |
| Mohandas, R | 2 |
| Beaver, TM | 1 |
| Johnson, RJ | 4 |
| Zafrani, L | 2 |
| Mooney, N | 1 |
| Majumdar, S | 1 |
| Sharma, N | 1 |
| Sengar, M | 1 |
| Thorat, J | 1 |
| Nayak, L | 1 |
| Bonda, A | 1 |
| Bagal, B | 1 |
| Rajendra, A | 1 |
| Sethi, A | 1 |
| Jain, H | 1 |
| Martens, KL | 2 |
| Khalighi, PR | 2 |
| Li, S | 2 |
| White, AA | 2 |
| Silgard, E | 2 |
| Frieze, D | 2 |
| Estey, E | 1 |
| Garcia, DA | 2 |
| Hingorani, S | 1 |
| Li, A | 2 |
| Cheng, FM | 1 |
| Tien, JZ | 1 |
| Chen, TT | 1 |
| Yeh, SP | 1 |
| Lin, CC | 1 |
| Diao, S | 1 |
| Nichols, ED | 1 |
| DiNardo, C | 1 |
| Konopleva, M | 1 |
| Ning, J | 1 |
| Qiao, W | 1 |
| Maiti, A | 1 |
| DiPippo, AJ | 1 |
| Javed, S | 1 |
| Hossain, S | 1 |
| Naber, M | 1 |
| Yacobucci, MJ | 1 |
| May, HP | 1 |
| Mara, KC | 1 |
| Barreto, EF | 2 |
| Leung, N | 2 |
| Habermann, TM | 2 |
| Russo, E | 1 |
| Viazzi, F | 1 |
| Kim, YK | 1 |
| Ham, JY | 1 |
| Lee, WK | 1 |
| Song, KE | 1 |
| Kishimoto, K | 2 |
| Kobayashi, R | 3 |
| Hori, D | 1 |
| Sano, H | 2 |
| Suzuki, D | 3 |
| Kobayashi, K | 2 |
| Heikamp, E | 1 |
| Dreyer, ZE | 1 |
| Boutin, A | 1 |
| Blackman, A | 1 |
| O'Sullivan, DM | 1 |
| Forcello, N | 1 |
| Bellos, I | 1 |
| Kontzoglou, K | 1 |
| Psyrri, A | 1 |
| Pergialiotis, V | 1 |
| Personett, HA | 1 |
| McCullough, KB | 1 |
| Dierkhising, R | 1 |
| McBride, A | 1 |
| Lathon, SC | 1 |
| Boehmer, L | 1 |
| Augustin, KM | 1 |
| Butler, SK | 1 |
| Westervelt, P | 1 |
| Feng, X | 1 |
| Dong, K | 1 |
| Pham, D | 2 |
| Pence, S | 1 |
| Inciardi, J | 1 |
| Bhutada, NS | 1 |
| Ishizawa, K | 1 |
| Canet, E | 1 |
| Cheminant, M | 1 |
| Thieblemont, C | 1 |
| Galicier, L | 1 |
| Lengline, E | 1 |
| Schnell, D | 1 |
| Reuter, D | 1 |
| Darmon, M | 1 |
| Schlemmer, B | 1 |
| Azoulay, E | 1 |
| Herrington, JD | 1 |
| Dinh, BC | 1 |
| Oka, Y | 1 |
| Tashiro, H | 1 |
| Sirasaki, R | 1 |
| Yamamoto, T | 1 |
| Akiyama, N | 1 |
| Kawasugi, K | 1 |
| Shirafuji, N | 1 |
| Fujimori, S | 1 |
| Norberg, SM | 1 |
| Oros, M | 1 |
| Birkenbach, M | 1 |
| Bilusic, M | 1 |
| Burns, RA | 1 |
| Topoz, I | 1 |
| Reynolds, SL | 1 |
| Cheuk, DK | 3 |
| Chiang, AK | 3 |
| Chan, GC | 3 |
| Ha, SY | 3 |
| Jayabose, S | 1 |
| Kumar, V | 1 |
| Dhanabalan, R | 1 |
| Rajan, P | 1 |
| Rathnam, K | 1 |
| Viswanathan, TK | 1 |
| Ichikawa, M | 2 |
| Yasuda, K | 1 |
| Iguchi, A | 1 |
| Takai, M | 1 |
| Yamauchi, T | 1 |
| Ookura, M | 1 |
| Matsuda, Y | 1 |
| Tai, K | 1 |
| Kishi, S | 1 |
| Yoshida, A | 1 |
| Iwasaki, H | 1 |
| Nakamura, T | 1 |
| Ueda, T | 2 |
| Pourafshar, N | 1 |
| Smallwood, BA | 1 |
| Hsu, JW | 1 |
| Pearson-Stuttard, B | 1 |
| Soutar, R | 1 |
| Leach, M | 2 |
| Spina, M | 1 |
| Nagy, Z | 1 |
| Ribera, JM | 1 |
| Federico, M | 1 |
| Aurer, I | 1 |
| Jordan, K | 1 |
| Borsaru, G | 1 |
| Pristupa, AS | 1 |
| Bosi, A | 1 |
| Grosicki, S | 1 |
| Glushko, NL | 1 |
| Ristic, D | 1 |
| Jakucs, J | 1 |
| Montesinos, P | 1 |
| Mayer, J | 1 |
| Rego, EM | 1 |
| Baldini, S | 1 |
| Scartoni, S | 1 |
| Capriati, A | 1 |
| Maggi, CA | 1 |
| Simonelli, C | 1 |
| Prasada, H | 1 |
| Platteborze, PL | 1 |
| Wilhelms, KW | 1 |
| Tamura, K | 1 |
| Kawai, Y | 1 |
| Kiguchi, T | 1 |
| Okamoto, M | 1 |
| Kaneko, M | 1 |
| Maemondo, M | 1 |
| Gemba, K | 1 |
| Fujimaki, K | 1 |
| Kirito, K | 1 |
| Goto, T | 1 |
| Fujisaki, T | 1 |
| Takeda, K | 1 |
| Nakajima, A | 1 |
| Patel, KS | 1 |
| Lau, JE | 1 |
| Zembillas, AS | 1 |
| Gallagher, EM | 1 |
| Koratala, A | 1 |
| Singhania, G | 1 |
| Alquadan, KF | 1 |
| Shimada, M | 2 |
| Dupré, A | 1 |
| Mousseaux, C | 1 |
| Bouguerba, A | 1 |
| Ayed, S | 1 |
| Barchazs, J | 1 |
| Boukari, M | 1 |
| Goldgran-Toledano, D | 1 |
| Bornstain, C | 1 |
| Vincent, F | 1 |
| Cairo, MS | 3 |
| Thompson, S | 1 |
| Tangirala, K | 1 |
| Eaddy, MT | 1 |
| Shaikh, SA | 1 |
| Marini, BL | 1 |
| Hough, SM | 1 |
| Perissinotti, AJ | 1 |
| Góth, L | 1 |
| Campara, M | 1 |
| Shord, SS | 1 |
| Haaf, CM | 1 |
| May, WS | 1 |
| Lingegowda, V | 1 |
| Sood, P | 1 |
| Nakagawa, T | 1 |
| Van, QC | 1 |
| Dass, B | 1 |
| Kikuchi, A | 1 |
| Kigasawa, H | 1 |
| Tsurusawa, M | 1 |
| Kawa, K | 1 |
| Kikuta, A | 1 |
| Tsuchida, M | 1 |
| Nagatoshi, Y | 1 |
| Asami, K | 1 |
| Horibe, K | 1 |
| Makimoto, A | 1 |
| Tsukimoto, I | 1 |
| Knoebel, RW | 1 |
| Lo, M | 1 |
| Crank, CW | 1 |
| Giraldez, M | 1 |
| Puto, K | 1 |
| Chubb, EA | 1 |
| Maloney, D | 1 |
| Farley-Hills, E | 2 |
| Ozkan, G | 1 |
| Ulusoy, S | 1 |
| Sönmez, M | 1 |
| Kaynar, K | 1 |
| Karagülle, M | 1 |
| Cortes, J | 1 |
| Moore, JO | 1 |
| Maziarz, RT | 1 |
| Wetzler, M | 1 |
| Craig, M | 1 |
| Matous, J | 1 |
| Luger, S | 1 |
| Dey, BR | 1 |
| Schiller, GJ | 1 |
| Abboud, CN | 1 |
| Krishnamurthy, M | 1 |
| Brown, A | 1 |
| Laadem, A | 1 |
| Seiter, K | 1 |
| Vines, AN | 1 |
| Shanholtz, CB | 2 |
| Thompson, JL | 1 |
| El-Husseini, A | 1 |
| Sabucedo, A | 1 |
| Lamarche, J | 1 |
| Courville, C | 1 |
| Peguero, A | 1 |
| Nakajima, M | 1 |
| Inamoto, J | 1 |
| Cho, Y | 1 |
| Kaneda, M | 1 |
| Yoshida, M | 1 |
| Ariga, T | 1 |
| Basturk, A | 1 |
| Hacibekiroglu, T | 1 |
| Akinci, S | 1 |
| Dilek, I | 1 |
| Atalay, HV | 1 |
| Vadhan-Raj, S | 1 |
| Fayad, LE | 1 |
| Fanale, MA | 1 |
| Pro, B | 1 |
| Rodriguez, A | 1 |
| Hagemeister, FB | 1 |
| Bueso-Ramos, CE | 1 |
| Zhou, X | 1 |
| McLaughlin, PW | 1 |
| Fowler, N | 1 |
| Shah, J | 1 |
| Orlowski, RZ | 1 |
| Samaniego, F | 1 |
| Wang, M | 1 |
| Cortes, JE | 1 |
| Younes, A | 1 |
| Kwak, LW | 1 |
| Sarlis, NJ | 1 |
| Romaguera, JE | 1 |
| Chiang, J | 1 |
| Chan, A | 1 |
| Lian, T | 1 |
| Tay, K | 1 |
| Quek, R | 1 |
| Tao, M | 1 |
| Lim, ST | 1 |
| Malaguarnera, G | 1 |
| Giordano, M | 1 |
| Malaguarnera, M | 2 |
| Lindeman, NI | 1 |
| Melanson, SE | 1 |
| McDonnell, A | 1 |
| DeAngelo, DJ | 1 |
| Jarolim, P | 1 |
| Cabanillas, F | 1 |
| Hussain, K | 1 |
| Mazza, JJ | 1 |
| Clouse, LH | 1 |
| Lee, AC | 1 |
| Li, CH | 1 |
| So, KT | 1 |
| Chan, R | 1 |
| Coiffier, B | 1 |
| Mounier, N | 1 |
| Bologna, S | 1 |
| Fermé, C | 1 |
| Tilly, H | 1 |
| Sonet, A | 1 |
| Christian, B | 1 |
| Casasnovas, O | 1 |
| Jourdan, E | 1 |
| Belhadj, K | 1 |
| Herbrecht, R | 1 |
| Milano, GM | 1 |
| De Sio, L | 1 |
| Cozza, R | 1 |
| Donfrancesco, A | 1 |
| van den Berg, H | 1 |
| Reintsema, AM | 1 |
| Krych, M | 1 |
| Dreyling, M | 1 |
| Kneba, M | 1 |
| Hoelzer, D | 1 |
| Hiddemann, W | 1 |
| Hallek, M | 1 |
| Arnold, TM | 1 |
| Reuter, JP | 1 |
| Delman, BS | 1 |
| Vogt, B | 1 |
| Gugger, M | 1 |
| Frey, FJ | 1 |
| de Bont, JM | 1 |
| Pieters, R | 1 |
| Lameire, NH | 1 |
| Flombaum, CD | 1 |
| Moreau, D | 1 |
| Ronco, C | 1 |
| Hummel, M | 1 |
| Buchheidt, D | 1 |
| Reiter, S | 1 |
| Bergmann, J | 1 |
| Adam, K | 1 |
| Hehlmann, R | 1 |
| Wang, LY | 1 |
| Shih, LY | 1 |
| Chang, H | 1 |
| Jou, ST | 1 |
| Lin, KH | 1 |
| Yeh, TC | 1 |
| Lin, SF | 1 |
| Liang, DC | 1 |
| Trifilio, S | 1 |
| Gordon, L | 1 |
| Singhal, S | 1 |
| Tallman, M | 1 |
| Evens, A | 1 |
| Rashid, K | 1 |
| Fishman, M | 1 |
| Masino, K | 1 |
| Pi, J | 1 |
| Mehta, J | 1 |
| McDonnell, AM | 1 |
| Lenz, KL | 1 |
| Frei-Lahr, DA | 1 |
| Hayslip, J | 1 |
| Hall, PD | 1 |
| Roy-Chaudhury, P | 1 |
| Cameron, JS | 1 |
| Kizer, N | 1 |
| Martinez, E | 1 |
| Powell, M | 1 |
| Cammalleri, L | 1 |
| Méhes, L | 1 |
| Udvardy, M | 1 |
| Szász, R | 1 |
| Rejto, L | 1 |
| Tiu, RV | 1 |
| Mountantonakis, SE | 1 |
| Dunbar, AJ | 1 |
| Schreiber, MJ | 1 |
| Teo, WY | 1 |
| Loh, TF | 1 |
| Tan, AM | 1 |
| Hochberg, J | 1 |
| Kattan, J | 1 |
| Culine, S | 1 |
| Tavakoli-Razavi, T | 1 |
| Kramar, A | 1 |
| Droz, JP | 1 |
| Hochman, I | 1 |
| Peer, G | 1 |
| Grosskopf, I | 1 |
| Goor, Y | 1 |
| Cabili, S | 1 |
| Jones, DP | 1 |
| Mahmoud, H | 1 |
| Chesney, RW | 1 |
| Pichette, V | 1 |
| Leblanc, M | 1 |
| Bonnardeaux, A | 1 |
| Ouimet, D | 1 |
| Geadah, D | 1 |
| Cardinal, J | 1 |
| Hande, KR | 1 |
| Garrow, GC | 1 |
| Saccente, SL | 1 |
| Kohaut, EC | 1 |
| Berkow, RL | 1 |
| Ichida, K | 1 |
| Hikita, M | 1 |
| Hosoya, T | 1 |
| Iwata, J | 1 |
| Masera, G | 1 |
| Jankovic, M | 1 |
| Ten Harkel, AD | 1 |
| Kist-Van Holthe, JE | 1 |
| Van Weel, M | 1 |
| Van der Vorst, MM | 1 |
| Mahmoud, HH | 1 |
| Leverger, G | 1 |
| Patte, C | 2 |
| Harvey, E | 2 |
| Lascombes, F | 1 |
| Parsons, RM | 1 |
| Reilly, JT | 1 |
| Winfield, DA | 1 |
| Chantada, GL | 1 |
| Sackmann-Muriel, F | 1 |
| Castro, MP | 1 |
| VanAuken, J | 1 |
| Spencer-Cisek, P | 1 |
| Legha, S | 1 |
| Sponzo, RW | 1 |
| Haas, M | 1 |
| Ohler, L | 1 |
| Watzke, H | 1 |
| Böhmig, G | 1 |
| Prokesch, R | 1 |
| Druml, W | 1 |
| Smalley, RV | 1 |
| Guaspari, A | 1 |
| Haase-Statz, S | 1 |
| Anderson, SA | 1 |
| Cederberg, D | 1 |
| Hohneker, JA | 1 |
| Blanke, CD | 1 |
| Hemmer, MP | 1 |
| Witte, RS | 1 |
| Jaing, TH | 1 |
| Hsueh, C | 1 |
| Tain, YL | 1 |
| Hung, IJ | 1 |
| Hsia, SH | 1 |
| Kao, CC | 1 |
| Byrne, AJ | 1 |
| Brennan, L | 1 |
| Sartori, P | 1 |
| Goldman, SC | 1 |
| Holcenberg, JS | 1 |
| Finklestein, JZ | 1 |
| Hutchinson, R | 1 |
| Kreissman, S | 1 |
| Johnson, FL | 1 |
| Tou, C | 1 |
| Morris, E | 1 |
| Sakiroglu, O | 1 |
| Sommelet, D | 1 |
| Pui, CH | 1 |
| Hsu, HH | 1 |
| Lin, CL | 1 |
| Chen, YC | 1 |
| Fang, JT | 1 |
| Huang, CC | 1 |
| Penel, N | 1 |
| Kouto, H | 1 |
| Ala-Eddine, C | 1 |
| Degardin, M | 1 |
| Thomas, CR | 1 |
| Dodhia, N | 1 |
| Heney, D | 1 |
| Essex-Cater, A | 1 |
| Brocklebank, JT | 1 |
| Bailey, CC | 1 |
| Lewis, IJ | 1 |
| O'Connor, NT | 1 |
| Prentice, HG | 1 |
| Hoffbrand, AV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol[NCT01724528] | Phase 3 | 346 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Phase 2 Study of Rasburicase Administered by Two Different Schedules (Fixed Dosing vs. As Needed Dosing) in Patients at High Risk or Potential Risk for Tumor Lysis Syndrome[NCT00628628] | Phase 2 | 82 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assessment of CTLS, from Day 3 to Day 8. According to Cairo-Bishop definition, CTLS is defined by the presence of LTLS in addition to 1 or more of the following significant clinical complications: renal insufficiency, cardiac arrhythmias, sudden death and seizures. The grade of CTLS is defined by the maximal grade of the clinical manifestation (NCT01724528)
Timeframe: 6 days
| Intervention | % of patients with CTLS occurrence (Number) |
|---|---|
| Febuxostat | 1.7 |
| Allopurinol | 1.2 |
Assessment of LTLS, from Day 3 to Day 8. According to Cairo-Bishop definition LTLS is defined by the presence of 2 or more laboratory abnormalities including: a 25% increase or levels above normal for serum uric acid, potassium, and phosphate or a 25% decrease or levels below normal for calcium. (NCT01724528)
Timeframe: 6 days
| Intervention | % of patients with LTLS occurrence (Number) |
|---|---|
| Febuxostat | 8.1 |
| Allopurinol | 9.2 |
Change in serum creatinine level from baseline (Day 1) to the evaluation visit (Day 8) (NCT01724528)
Timeframe: 8 days
| Intervention | change % (Mean) |
|---|---|
| Febuxostat | -0.83 |
| Allopurinol | -4.92 |
Area under the curve of sUA from baseline (Day 1) to the evaluation visit (Day 8) (NCT01724528)
Timeframe: 8 days
| Intervention | mg x hour/dL (Mean) |
|---|---|
| Febuxostat | 514.0 |
| Allopurinol | 708.0 |
Assessment of treatment responder rate, where treatment response is defined as the maintenance of sUA ≤ 7.5 mg/dL from Day 3 to Day 8 (NCT01724528)
Timeframe: 6 days
| Intervention | % of patients who fail to respond (Number) |
|---|---|
| Febuxostat | 1.7 |
| Allopurinol | 4.0 |
Plasma UA response is defined as normalization of plasma UA levels within 48 hours after the start of study drug (rasburicase) and maintaining within the normal range after the final drug infusion on day 5. Plasma samples for UA were collected at baseline before rasburicase, 4- and 24-hours post-rasburicase, and daily during treatment. (NCT00628628)
Timeframe: First cycle of chemotherapy, up to 5 days
| Intervention | participants (Number) |
|---|---|
| Group A: Single Dose | 39 |
| Group B: Daily Dose | 34 |
25 reviews available for uric acid and Tumour Lysis Syndrome
| Article | Year |
|---|---|
Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis.
Topics: Allopurinol; Animals; Febuxostat; Gout Suppressants; Humans; Tumor Lysis Syndrome; Uric Acid | 2019 |
Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Female; Humans; Hyperuricemia; Middle Aged; | 2013 |
[Tumor lysis syndrome].
Topics: Calcium; Humans; Potassium; Practice Guidelines as Topic; Risk Assessment; Tumor Lysis Syndrome; Uri | 2013 |
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Topics: Adolescent; Allopurinol; Antimetabolites; Area Under Curve; Child; Controlled Clinical Trials as Top | 2014 |
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Topics: Adolescent; Allopurinol; Antimetabolites; Area Under Curve; Child; Controlled Clinical Trials as Top | 2017 |
[Rasburicase therapy may cause hydrogen peroxide shock].
Topics: Gout Suppressants; Hemolysis; Humans; Hydrogen Peroxide; Hyperuricemia; Methemoglobin; Shock; Tumor | 2008 |
Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
Topics: Allopurinol; Antimetabolites; Child; Controlled Clinical Trials as Topic; Humans; Neoplasms; Randomi | 2010 |
Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.
Topics: Adult; Aged; Aged, 80 and over; Asia; Burkitt Lymphoma; Creatinine; Female; Humans; L-Lactate Dehydr | 2011 |
Rasburicase for the treatment of tumor lysis in hematological malignancies.
Topics: Hematologic Neoplasms; Humans; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2012 |
Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Blood Urea Nitrogen; Calcium; Creatinine; Fatal Outcome; Fluid Therapy; | 2003 |
[Prophylaxis and differential therapy of tumorlysis syndrome].
Topics: Allopurinol; Antimetabolites; Antineoplastic Agents; Cost-Benefit Analysis; Enzyme Inhibitors; Human | 2004 |
Management of hyperuricemia with rasburicase review.
Topics: Allopurinol; Antimetabolites; Clinical Trials as Topic; Cost-Benefit Analysis; Free Radical Scavenge | 2004 |
Acute renal failure in cancer patients.
Topics: Acute Kidney Injury; Antineoplastic Agents; Humans; Hyperuricemia; Neoplasms; Prognosis; Risk Factor | 2005 |
Uric Acid and renal disease.
Topics: Humans; Hyperuricemia; Kidney; Kidney Calculi; Kidney Diseases; Kidney Glomerulus; Models, Biologica | 2006 |
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2007 |
[The pathophysiology, clinical signs and therapy of urate nephropathy].
Topics: Acidosis; Acute Kidney Injury; Allopurinol; Fluid Therapy; Humans; Hyperkalemia; Kidney Tubules; Rec | 2007 |
Tumor lysis syndrome.
Topics: Biomarkers; Humans; Kidney Diseases; Neoplasms; Tumor Lysis Syndrome; Uric Acid | 2007 |
Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
Topics: Burkitt Lymphoma; Child; Humans; Hyperuricemia; Male; Renal Dialysis; Singapore; Treatment Outcome; | 2007 |
Tumor lysis syndrome: pathogenesis and management.
Topics: Acute Kidney Injury; Humans; Kidney Diseases; Renal Dialysis; Risk Factors; Tumor Lysis Syndrome; Ur | 1995 |
Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma.
Topics: Acute Disease; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Bur | 1993 |
[Hyperuricemia and the kidney].
Topics: Acute Kidney Injury; Allopurinol; Gout; Humans; Hydrogen-Ion Concentration; Kidney; Renal Dialysis; | 1996 |
[Hyperuricemia in hematological disorders].
Topics: Bone Marrow; Bone Marrow Diseases; Hematologic Diseases; Humans; Kidney Diseases; Necrosis; Tumor Ly | 1996 |
Advances in the management of malignancy-associated hyperuricaemia.
Topics: Allopurinol; Antineoplastic Agents; Aspergillus flavus; Gout Suppressants; Humans; Male; Recombinant | 1998 |
Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Calcium; | 1999 |
Common emergencies in cancer medicine: metabolic syndromes.
Topics: Acidosis, Lactic; Acute Kidney Injury; Adrenal Cortex Diseases; Emergencies; Humans; Hypercalcemia; | 1991 |
9 trials available for uric acid and Tumour Lysis Syndrome
| Article | Year |
|---|---|
A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome.
Topics: Adolescent; Adult; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Tumor Lysis Syndrome; Ur | 2023 |
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Febuxostat; Female; Follow-Up Stud | 2015 |
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Febuxostat; Female; Follow-Up Stud | 2015 |
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Febuxostat; Female; Follow-Up Stud | 2015 |
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Febuxostat; Female; Follow-Up Stud | 2015 |
Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hy | 2016 |
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Hypersensi | 2009 |
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Agents | 2010 |
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gout Suppressants; Humans; Lymphoma, | 2012 |
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on R
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Creatinine; Female; Humans; Hyperuricemia; In | 2003 |
Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Calcium; Child; Child, Preschool; Female; Hematologic Ne | 2006 |
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Topics: Adolescent; Allopurinol; Child; Child, Preschool; Creatinine; Drugs, Investigational; Female; Humans | 2001 |
78 other studies available for uric acid and Tumour Lysis Syndrome
| Article | Year |
|---|---|
Fixed-Dose Recombinant Urate Oxidase in the Treatment of Paediatric Tumour Lysis Syndrome: A Regional Cancer Centre Experience.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Male; Retrospective Studies; Treatment Outcome; | 2021 |
Crystals or His(stones): Rethinking AKI in Tumor Lysis Syndrome.
Topics: Acute Kidney Injury; Humans; Tumor Lysis Syndrome; Uric Acid | 2022 |
Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.
Topics: B-Cell Maturation Antigen; Cell- and Tissue-Based Therapy; Creatinine; Humans; Multiple Myeloma; Rec | 2022 |
A Crystal-Independent Role for Uric Acid in AKI Associated with Tumor Lysis Syndrome.
Topics: Acute Kidney Injury; Humans; Hyperuricemia; Tumor Lysis Syndrome; Uric Acid | 2023 |
Authors' Reply: A Crystal-Independent Role for Uric Acid in AKI Associated with Tumor Lysis Syndrome.
Topics: Acute Kidney Injury; Humans; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2023 |
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
Topics: Adult; Allopurinol; Female; Humans; Hyperuricemia; Kaplan-Meier Estimate; Male; Middle Aged; Neoplas | 2020 |
Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitid | 2020 |
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, | 2021 |
Urate Nephropathy from Tumor Lysis Syndrome in an Undiagnosed Case of Prostate Cancer.
Topics: Hemolytic-Uremic Syndrome; Humans; Male; Prostatic Neoplasms; Purpura, Thrombotic Thrombocytopenic; | 2021 |
A retrospective observational study of a low fixed-dose rasburicase protocol for the treatment of tumor lysis syndrome in adults.
Topics: Adult; Cohort Studies; Gout Suppressants; Humans; Hyperuricemia; Observational Studies as Topic; Ret | 2022 |
Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome.
Topics: Adult; Area Under Curve; Humans; Kidney; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2021 |
Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome.
Topics: Adult; Creatinine; Humans; Kidney; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2021 |
Spontaneous tumour lysis syndrome in cervical cancer.
Topics: Adult; Calcium; Carcinoma, Squamous Cell; Fatal Outcome; Female; Humans; Hysterectomy; Lymphatic Met | 2017 |
Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies.
Topics: Adolescent; Age Factors; Allopurinol; Antineoplastic Agents; Biomarkers; Child; Child, Preschool; Cr | 2017 |
50 Years Ago in The Journal of Pediatrics: Prevention and Management of Acute Hyperuricemia in Childhood Leukemia.
Topics: Acute Disease; Allopurinol; Child; DNA, Neoplasm; History, 20th Century; Humans; Hyperuricemia; Merc | 2017 |
The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Topics: Aged; Aged, 80 and over; Body Weight; Cost Savings; Female; Gout Suppressants; Hospitalization; Huma | 2019 |
Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Topics: Acute Kidney Injury; Aged; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Neop | 2020 |
Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Incidence | 2019 |
Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
Topics: Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Gout Suppressants; Huma | 2013 |
Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
Topics: Acute Kidney Injury; Adult; Aged; Biomarkers; Female; Follow-Up Studies; Hematologic Neoplasms; Huma | 2014 |
Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Drug Costs; Female; Gout Suppressants; Hospital Costs; H | 2015 |
Hyperuricemia in hematologic malignancies is caused by an insufficient urinary excretion.
Topics: Aged; Female; Hematologic Neoplasms; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Retrospective | 2014 |
Spontaneous tumor lysis syndrome in renal cell carcinoma: a case report.
Topics: Carcinoma, Renal Cell; Hematuria; Humans; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Ag | 2014 |
Tumor lysis syndrome: risk factors, diagnosis, and management.
Topics: Allopurinol; Burkitt Lymphoma; Child; Creatinine; Electrolytes; Fluid Therapy; Gout Suppressants; Hu | 2014 |
Low-dose rasburicase in hematologic malignancies.
Topics: Adolescent; Child; Child, Preschool; Female; Gout Suppressants; Hematologic Neoplasms; Humans; India | 2015 |
Risk factors for tumor lysis syndrome in childhood acute myeloid leukemia treated with a uniform protocol without rasburicase prophylaxis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Child; Child, Pres | 2015 |
Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Topics: Aged; Allopurinol; Antineoplastic Agents; Creatinine; Enzyme Inhibitors; Febuxostat; Female; Glomeru | 2014 |
Uric acid and the prediction models of tumor lysis syndrome in AML.
Topics: Acute Kidney Injury; Antineoplastic Agents; Biomarkers; Female; Humans; Incidence; Leukemia, Myeloid | 2015 |
Acute kidney injury from tumour lysis syndrome and urate crystalluria.
Topics: Acute Kidney Injury; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Radiography; Tumor | 2015 |
Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia.
Topics: Child; Humans; Hyperphosphatemia; Male; Phosphates; Sevelamer; Tumor Lysis Syndrome; Uric Acid | 2015 |
Request for Uric Acid Analysis on an Iced Specimen.
Topics: Child; Cold Temperature; Female; Gout Suppressants; Humans; Precursor Cell Lymphoblastic Leukemia-Ly | 2015 |
Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Topics: Aged; Disease Progression; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Over | 2017 |
Serum Uric Acid Exhibits Inverse Relationship with Estimated Glomerular Filtration Rate.
Topics: Acute Kidney Injury; Cohort Studies; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney | 2016 |
[Analysis of the 2015 British guidelines on the prevention and management of tumor lysis syndrome].
Topics: Adult; Allopurinol; Child; Hematologic Neoplasms; Humans; Incidence; Neoplasms; Practice Guidelines | 2017 |
A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
Topics: Allopurinol; Female; Gout Suppressants; Hospitalization; Humans; Hyperuricemia; Length of Stay; Male | 2017 |
Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Topics: Acute Kidney Injury; Adult; Aged; Cohort Studies; Disease Management; Female; Gout Suppressants; Hum | 2018 |
Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
Topics: Aged; Antineoplastic Agents; Creatinine; Drug Costs; Female; Gout Suppressants; Humans; Hyperuricemi | 2009 |
A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome.
Topics: Acute Kidney Injury; Animals; Crystallization; Humans; Tumor Lysis Syndrome; Uric Acid | 2009 |
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Body Weight; Chicago; Cost Savings; Cost-Benefit Analysi | 2011 |
A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults.
Topics: Adolescent; Adult; Hematologic Neoplasms; Humans; Male; Retrospective Studies; Treatment Outcome; Tu | 2010 |
Tumour lysis syndrome: an unusual presentation.
Topics: Burkitt Lymphoma; Humans; Intestinal Neoplasms; Male; Middle Aged; Postoperative Complications; Tumo | 2010 |
Treatment of tumor lysis syndrome with the highest known uric acid level.
Topics: Humans; Male; Renal Dialysis; Tumor Lysis Syndrome; Uric Acid; Young Adult | 2010 |
Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Dose-Response Relationship, Drug; Drug Administration Sc | 2010 |
Acute kidney injury associated with tumor lysis syndrome: a paradigm shift.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Calcium; Creatinine; Humans; Hyperuricemia; Lympho | 2012 |
Higher urinary excretion of inorganic phosphate during early induction chemotherapy predicts a good prognosis in childhood acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Child; Child, Preschool; Fem | 2011 |
Is there any protective effect on organs upon higher uric acid level in tumor lysis syndrome?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-AB | 2011 |
Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase.
Topics: Blood Chemical Analysis; Humans; Refrigeration; Specimen Handling; Tumor Lysis Syndrome; Urate Oxida | 2013 |
Metabolic abnormalities in lymphoma.
Topics: Adult; Allopurinol; Anthracyclines; Cell Division; Creatinine; Enzyme Inhibitors; Humans; Hypocalcem | 2002 |
Treatment of impending tumor lysis with single-dose rasburicase.
Topics: Adolescent; Child; Child, Preschool; Humans; Hyperuricemia; Male; Precursor Cell Lymphoblastic Leuke | 2003 |
Tumor lysis syndrome and neuroblastoma.
Topics: Antineoplastic Agents; Child; Humans; L-Lactate Dehydrogenase; Neuroblastoma; Tumor Lysis Syndrome; | 2003 |
Renal tubular damage in rasburicase: risks of alkalinisation.
Topics: Alkalies; Burkitt Lymphoma; Calcium Phosphates; Child; Creatine; Dialysis; Humans; Hydrogen-Ion Conc | 2004 |
Use of single-dose rasburicase in an obese female.
Topics: Allopurinol; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Leukemia, Myelogen | 2004 |
[Rasburicase (Fasturtec)].
Topics: Crystallization; Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Kidney Failure, Chronic; K | 2004 |
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; C | 2005 |
Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Female; Hematopoietic Stem Cell Transplantation; Humans; | 2006 |
Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
Topics: Adult; Creatinine; Dose-Response Relationship, Drug; Female; Gout Suppressants; Humans; Male; Middle | 2006 |
Spontaneous self-alkalinization in spontaneous tumor lysis syndrome.
Topics: Humans; Hydrogen-Ion Concentration; Kidney Calculi; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffus | 2006 |
Report of two cases of rasburicase-induced methemoglobinemia.
Topics: Acquired Immunodeficiency Syndrome; Humans; Hyperuricemia; Lymphoma, AIDS-Related; Lymphoma, Large B | 2006 |
Tumor lysis syndrome: current perspective.
Topics: Allopurinol; Area Under Curve; Hematologic Neoplasms; Humans; Medical Oncology; Models, Biological; | 2008 |
Acute tumor lysis syndrome in poor-risk germ cell tumors: does it exist?
Topics: Acute Disease; Adolescent; Adult; Alkalies; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1994 |
Uric acid nephropathy as a presenting sign of chronic lymphocytic leukemia.
Topics: Humans; Kidney Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Lysis Synd | 1995 |
High dialysate flow rate continuous arteriovenous hemodialysis: a new approach for the treatment of acute renal failure and tumor lysis syndrome.
Topics: Acute Kidney Injury; Blood Urea Nitrogen; Calcium; Creatinine; Hemodialysis Solutions; Humans; Male; | 1994 |
Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Burkitt Lymphoma; Child; Child, | 1995 |
Tumor lysis syndrome, case report and review of the literature.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Leukemia- | 1997 |
Alkalinization and the tumor lysis syndrome.
Topics: Adolescent; Bicarbonates; Fluid Therapy; Furosemide; Humans; Hypocalcemia; Lymphoma, Non-Hodgkin; Ma | 1998 |
Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy.
Topics: Aged; Allantoin; Antimetabolites, Antineoplastic; Diuresis; Drug Evaluation; Female; Humans; Kidney | 1998 |
Alkalinization and tumor lysis syndrome.
Topics: Humans; Hydrogen-Ion Concentration; Retrospective Studies; Tumor Lysis Syndrome; Uric Acid | 1999 |
The spectrum of acute renal failure in tumour lysis syndrome.
Topics: Acute Kidney Injury; Adult; Female; Humans; Hypophosphatemia; Male; Tumor Lysis Syndrome; Uric Acid | 1999 |
Allopurinol: intravenous use for prevention and treatment of hyperuricemia.
Topics: Adult; Allopurinol; Child; Enzyme Inhibitors; Humans; Infusions, Intravenous; Kidney Diseases; Neopl | 2000 |
Acute tumor lysis syndrome with choriocarcinoma.
Topics: Acidosis; Acute Disease; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2000 |
Tumor lysis syndrome in an infant with Langerhans cell histiocytosis successfully treated using continuous arteriovenous hemofiltration.
Topics: Acute Kidney Injury; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood | 2001 |
Tumour lysis syndrome during anaesthesia.
Topics: Abdomen; Anesthesia; Biopsy; Child, Preschool; Female; Humans; Hyperkalemia; Hypocalcemia; Lymphoma, | 2001 |
European experience in the treatment of hyperuricemia.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Europe; Female | 2001 |
Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Child; Clinical T | 2001 |
An enormous abdominal mass associated with acute renal failure.
Topics: Abdominal Neoplasms; Acute Kidney Injury; Aged; Biopsy, Needle; Burkitt Lymphoma; Follow-Up Studies; | 2001 |
[Tumor lysis syndrome with symptomatic hyperuricemia after a first chemotherapeutic treatment of undifferentiated carcinoma of the cavum].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2002 |
Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome.
Topics: Child; Creatinine; Hemofiltration; Humans; Male; Phosphates; Phosphorus; Tumor Lysis Syndrome; Urea; | 1990 |
Prevention of urate nephropathy in the tumour lysis syndrome.
Topics: Adolescent; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Diuresis; Hum | 1989 |